BACKGROUND Incidence of and mortality from colorectal cancer (CRC) can be effectively reduced by screening with the fecal immunochemical test (FIT) or colonoscopy. Individual risk to develop CRC within 15 years varies from 15% among people aged 50 to 75 years. Communicating personalized CRC risk and appropriate screening recommendations could improve the risk-benefit balance of screening test allocations and optimize the use of limited colonoscopy resources. However, significant uncertainty exists regarding the feasibility and efficacy of risk-based screening. OBJECTIVE We aim to study the effect of communicating individual CRC risk and a risk-based recommendation of the FIT or colonoscopy on participants' choice of screening test....
Faecal immunochemical testing (FIT) is increasingly used in colorectal cancer (CRC) screening but ha...
Background. Individuals at average risk for colorectal cancer (CRC) have multiple test options. Pref...
Background: Colorectal cancer (CRC) is the second most prevalent type of cancer in Europe. Early det...
BackgroundIncidence of and mortality from colorectal cancer (CRC) can be effectively reduced by scre...
Background In Scotland a new, easier to complete bowel screening test, the Faecal Immunochemical Tes...
Background There is currently no existing evidence on the effects of personalised risk information o...
Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-b...
Colorectal cancer (CRC) screening has been demonstrated to reduce CRC incidence and mortality. Howev...
Opinion statementColorectal cancer (CRC) imposes significant morbidity and mortality, yet it is also...
Colorectal cancer (CRC) screening has been demonstrated to reduce CRC incidence and mortality. Howev...
Opinion statementColorectal cancer (CRC) imposes significant morbidity and mortality, yet it is also...
poster abstractAbstract: While colonoscopy is the most prevalent screening test for colorectal canc...
Background Provider recommendation is a predictor of colorectal cancer (CRC) screening. Purpose ...
textabstractObjective Faecal immunochemical testing (FIT) is increasingly used in colorectal cancer ...
Objective Faecal immunochemical testing (FIT) is increasingly used in colorectal cancer (CRC) screen...
Faecal immunochemical testing (FIT) is increasingly used in colorectal cancer (CRC) screening but ha...
Background. Individuals at average risk for colorectal cancer (CRC) have multiple test options. Pref...
Background: Colorectal cancer (CRC) is the second most prevalent type of cancer in Europe. Early det...
BackgroundIncidence of and mortality from colorectal cancer (CRC) can be effectively reduced by scre...
Background In Scotland a new, easier to complete bowel screening test, the Faecal Immunochemical Tes...
Background There is currently no existing evidence on the effects of personalised risk information o...
Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-b...
Colorectal cancer (CRC) screening has been demonstrated to reduce CRC incidence and mortality. Howev...
Opinion statementColorectal cancer (CRC) imposes significant morbidity and mortality, yet it is also...
Colorectal cancer (CRC) screening has been demonstrated to reduce CRC incidence and mortality. Howev...
Opinion statementColorectal cancer (CRC) imposes significant morbidity and mortality, yet it is also...
poster abstractAbstract: While colonoscopy is the most prevalent screening test for colorectal canc...
Background Provider recommendation is a predictor of colorectal cancer (CRC) screening. Purpose ...
textabstractObjective Faecal immunochemical testing (FIT) is increasingly used in colorectal cancer ...
Objective Faecal immunochemical testing (FIT) is increasingly used in colorectal cancer (CRC) screen...
Faecal immunochemical testing (FIT) is increasingly used in colorectal cancer (CRC) screening but ha...
Background. Individuals at average risk for colorectal cancer (CRC) have multiple test options. Pref...
Background: Colorectal cancer (CRC) is the second most prevalent type of cancer in Europe. Early det...